Pdl Biopharmaoriginally Founded As Protein Design Labsincin 1986Was A Pioneer In The Humanization Of Monoclonal Antibodiesthis Technology Played A Crucial Role In Developing Targeted Treatments For Diseases Such As Cancer And Immunologic Disordersthe Company Changed Its Name To Pdl Biopharma In 2006 And Managed A Portfolio Of Patents And Royalty Assetsentering Into Various License Agreements With Pharmaceutical And Biotechnology Companies Pdl Biopharma Specialized In Monoclonal Antibody Humanizationproviding Financing Solutions And Royalty Management Servicesthe Company Supported Public And Private Healthcare Firms By Offering Non Dilutive Growth Capital And Managing Royalty Streamsnotable Partnerships Included Collaborations With Biogen Idec And Abbvieparticularly In The Development Of Daclizumab For Multiple Sclerosiswhich Received Fda Approval In 2016 Under The Trade Name Zinbrytaas Of January 2021Pdl Biopharma Began A Liquidation Processconcluding Its Operations As A Standalone Entity
No conferences found for this company.
| Company Name | Pdl Biopharma Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
